AngioDynamics Inc (ANGO) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with ANGO
Recent news

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
ANGO

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
ANGO

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
ANGO

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
ANGO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 20.95
- MACD 12/26/9
- -0.66
- EMA 9 of MACD
- -0.22
- MACD histogram
- -0.44
- SMA 50
- $15.31
- Price below SMA 50
- EMA 50
- $14.74
- Price below EMA 50
- SMA 200
- $12.48
- Price below SMA 200
- EMA 200
- $13.13
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
ANGO

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
ANGO

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
ANGO

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
ANGO

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
ANGO

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
ANGO

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
ANGO

AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics to Participate in Upcoming Investor Conferences
ANGO

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
ANGO

AngioDynamics Q4 Earnings Call Highlights
AngioDynamics Q4 Earnings Call Highlights
ANGO
News tone: automated (AI) classification of the article's content, not a price prediction.
About AngioDynamics Inc
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. James C. Clemmer | CEO, President & Director | 1964 |
| Mr. Stephen A. Trowbridge | Executive VP & CFO | 1974 |
| Mr. Lawrence T. Weiss | Senior VP, Chief Legal Officer & Corporate Secretary | 1970 |
| Mr. Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | 1969 |
| Ms. Laura Piccinini | Senior VP and GM of Cardiovascular & International | 1969 |
| Mr. Saleem M. Cheeks | Vice President of Communications | — |
| Mr. Benjamin H. Davis | Senior Vice President of Business Development & Strategy | 1964 |
| Ms. Marna I. Bronfen-Moore | Senior Vice President of Human Resources | 1968 |
| Mr. Chad T. Campbell | Senior VP and GM of Oncology & Interventional Devices | 1971 |
| Ms. Kim L. Seabury | Senior Vice President of Information Technology | 1968 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 20.95
- MACD 12/26/9
- -0.66
- EMA 9 of MACD
- -0.22
- MACD histogram
- -0.44
- SMA 50
- $15.31
- Price below SMA 50
- EMA 50
- $14.74
- Price below EMA 50
- SMA 200
- $12.48
- Price below SMA 200
- EMA 200
- $13.13
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $19.00
- Average
- $19.50
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +10.3 | -12.3 | +8.2 | |||||||||
| 2022 | -25.8 | +10.4 | -10.2 | -6.5 | -7.1 | -1.6 | +16.1 | -5.0 | -5.0 | -31.0 | -8.0 | +8.2 |
| 2023 | -2.6 | -7.3 | -17.4 | -15.8 | +10.0 | +8.2 | -15.8 | -6.6 | -5.4 | -16.7 | +4.5 | +14.3 |
| 2024 | -26.5 | -8.7 | +6.7 | -0.7 | +9.0 | -5.5 | +37.1 | -4.2 | +6.3 | -12.3 | +3.7 | +28.3 |
| 2025 | +27.1 | -15.9 | +0.8 | -3.8 | +11.0 | +2.3 | -6.9 | +19.9 | +6.8 | +8.7 | +4.8 | -1.0 |
| 2026 | -18.3 | +9.8 | +0.1 | -8.4 | +2.9 | +19.2 | +13.1 | +6.3 | -3.0 | -23.8 |



